Law & Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Law & Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Bioscience
Immuneregen Biosciences Advances Toward Ind Filing; Homspera Clears Initial Toxicity Hurdle
August 16th, 2008
ImmuneRegen® BioSciences, Inc., a wholly owned subsidiary of IR BioSciences Holdings, Inc. (OTCBB:IRBO - News), announced findings from genotoxicity studies confirming that the lead drug candidate in development, Homspera®, does not cause DNA damage. The studies, conducted at both WuXi AppTec, Inc. and the IIT Research Institute, are currently required by the FDA as a component of pre-clinical safety testing necessary for Investigational New Drug (IND) acceptance and clearance to initiate human studies. Genotoxicity tests are designed to detect DNA damage caused by a potential drug candidate via various mechanisms, predicting one aspect of potential human risk. A...
Source: Law & Health Weekly (2008-08-16)
|
